Is BSX stock overvalued right now?

BSX is trading near our fair value estimate of $40.01, within a normal valuation band.

What is BSX fair value based on current fundamentals?

Our fair value estimate for BSX is $40.01, derived from discounted cash flow, dividend discount, and relative valuation multiples. The estimate assumes a discount rate of 9.0% and terminal growth of 2.5%.

How risky is BSX compared with other stocks?

BSX carries a beta of 0.57 suggests a defensive profile. Investors should weigh macro exposure against their own risk tolerance.

Is BSX still growing?

Latest trailing metrics show revenue growth of 7.5% and earnings growth of 15.1%. Profit margins are 17.5%.

What do analysts think about BSX?

Analyst consensus target is $62.00, implying 37.6% upside. The street recommendation is "buy".

What could change the investment case for BSX?

Key catalysts include Healthcare sector dynamics, interest rate shifts, and company-specific earnings surprises. Monitor macro risk scores and analyst estimate revisions for early signals.

HealthcareUpdated·Data: Yahoo Finance, SEC EDGAR·Data delayed ~5 min

Insight BSX High Conviction Pick Joint Venture result High

NYQ · Healthcare · Medical Devices

$45.05

+2.07 (+4.82%)

Stock valuation guide Macro risk explained guide

About the Author

Phasakorn Traklang (Peach) — Founder

Phasakorn Traklang (Peach) is the founder of QuantSoar, bringing expertise in SEO, web development, and technical analytics to build an AI-powered investment platform accessible to retail investors worldwide.

Connect on LinkedIn

Investment Disclaimer: QuantSoar is for informational purposes only. We do not provide personalized investment advice. Always conduct your own research or consult a financial advisor. SEC

Data: Yahoo Finance / SEC EDGAR / Alpha Vantage / Finnhub. AI outputs verified against source data.